New hope for brain cancer: CAR-T and stem cell combo trial launches
NCT ID NCT07198464
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 35 times
Summary
This study tests a combination of four treatments for primary central nervous system lymphoma (PCNSL), a rare and aggressive brain cancer. The approach uses the patient's own immune cells (CAR-T cells) and stem cells, plus two targeted drugs. The goal is to see if this powerful mix can improve how long patients live without the cancer growing back. The trial will enroll 30 adults aged 18-60 who have not had CAR-T or stem cell therapy before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
relmacabtagene autoleucel (CAR-T cells), autologous hematopoietic stem cells, orelabrutinib, and sintilimab
What this could lead to
If successful, this could offer a powerful new treatment option for a rare and aggressive brain lymphoma, potentially improving long-term survival.
What could go wrong
This is a small, early-phase study (30 people) with no control group, so results may not apply broadly. The combination therapy carries risks like severe immune reactions and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.